Selected research
Industry Research
Cobalamin API Industry Research Report 2026
Market perspective
The global Cobalamin API market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Cobalamin API is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Cobalamin API is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Cobalamin API is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Cobalamin API include Teva (Actavis), Novartis, Merck, Mylan, Pfizer, Huaxin Pharmaceutical, Sanofi-Aventis, RLG Group and Luitpold Pharmaceuticals (Daiichi Sankyo), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Cobalamin API market in terms of revenue (US$ million) and, where applicable, sales volume (t), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/t) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Cobalamin API Market by Company
Teva (Actavis)
Novartis
Merck
Mylan
Pfizer
Huaxin Pharmaceutical
Sanofi-Aventis
RLG Group
Luitpold Pharmaceuticals (Daiichi Sankyo)
Jamieson
Endo International
CCEPCD
Bayer HealthCare
ANGELINI
Cobalamin API Segment by Type
Purity≥99%
Purity<99%
Cobalamin API Segment by Application
Cobalamin Injection
Cobalamin Spray
Oral Cobalamin
Cobalamin API Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cobalamin API market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cobalamin API and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cobalamin API.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Cobalamin API manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Cobalamin API by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Cobalamin API in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Purity≥99%
- Purity<99%
Applications
- Cobalamin Injection
- Cobalamin Spray
- Oral Cobalamin
Companies covered
- Teva (Actavis)
- Novartis
- Merck
- Mylan
- Pfizer
- Huaxin Pharmaceutical
- Sanofi-Aventis
- RLG Group
- Luitpold Pharmaceuticals (Daiichi Sankyo)
- Jamieson
- Endo International
- CCEPCD
- Bayer HealthCare
- ANGELINI
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Cobalamin API Market Size (2021-2032)
- 2.2.2 Global Cobalamin API Sales (2021-2032)
- 2.2.3 Global Cobalamin API Market Average Price (2021-2032)
- 2.3 Cobalamin API by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Purity≥99%
- 2.3.3 Purity<99%
- 2.4 Cobalamin API by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Cobalamin Injection
- 2.4.3 Cobalamin Spray
- 2.4.4 Oral Cobalamin
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Cobalamin API Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Cobalamin API Sales (t) of Manufacturers (2021-2026)
- 3.3 Global Cobalamin API Revenue of Manufacturers (2021-2026)
- 3.4 Global Cobalamin API Average Price by Manufacturers (2021-2026)
- 3.5 Global Cobalamin API Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Cobalamin API, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Cobalamin API, Product Type & Application
- 3.8 Global Manufacturers of Cobalamin API, Established Date
- 3.9 Global Cobalamin API Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Teva (Actavis)
- 4.1.1 Teva (Actavis) Company Information
- 4.1.2 Teva (Actavis) Business Overview
- 4.1.3 Teva (Actavis) Cobalamin API Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Teva (Actavis) Cobalamin API Product Portfolio
- 4.1.5 Teva (Actavis) Recent Developments
- 4.2 Novartis
- 4.2.1 Novartis Company Information
- 4.2.2 Novartis Business Overview
- 4.2.3 Novartis Cobalamin API Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Novartis Cobalamin API Product Portfolio
- 4.2.5 Novartis Recent Developments
- 4.3 Merck
- 4.3.1 Merck Company Information
- 4.3.2 Merck Business Overview
- 4.3.3 Merck Cobalamin API Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Merck Cobalamin API Product Portfolio
- 4.3.5 Merck Recent Developments
- 4.4 Mylan
- 4.4.1 Mylan Company Information
- 4.4.2 Mylan Business Overview
- 4.4.3 Mylan Cobalamin API Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Mylan Cobalamin API Product Portfolio
- 4.4.5 Mylan Recent Developments
- 4.5 Pfizer
- 4.5.1 Pfizer Company Information
- 4.5.2 Pfizer Business Overview
- 4.5.3 Pfizer Cobalamin API Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Pfizer Cobalamin API Product Portfolio
- 4.5.5 Pfizer Recent Developments
- 4.6 Huaxin Pharmaceutical
- 4.6.1 Huaxin Pharmaceutical Company Information
- 4.6.2 Huaxin Pharmaceutical Business Overview
- 4.6.3 Huaxin Pharmaceutical Cobalamin API Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Huaxin Pharmaceutical Cobalamin API Product Portfolio
- 4.6.5 Huaxin Pharmaceutical Recent Developments
- 4.7 Sanofi-Aventis
- 4.7.1 Sanofi-Aventis Company Information
- 4.7.2 Sanofi-Aventis Business Overview
- 4.7.3 Sanofi-Aventis Cobalamin API Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Sanofi-Aventis Cobalamin API Product Portfolio
- 4.7.5 Sanofi-Aventis Recent Developments
- 4.8 RLG Group
- 4.8.1 RLG Group Company Information
- 4.8.2 RLG Group Business Overview
- 4.8.3 RLG Group Cobalamin API Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 RLG Group Cobalamin API Product Portfolio
- 4.8.5 RLG Group Recent Developments
- 4.9 Luitpold Pharmaceuticals (Daiichi Sankyo)
- 4.9.1 Luitpold Pharmaceuticals (Daiichi Sankyo) Company Information
- 4.9.2 Luitpold Pharmaceuticals (Daiichi Sankyo) Business Overview
- 4.9.3 Luitpold Pharmaceuticals (Daiichi Sankyo) Cobalamin API Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Luitpold Pharmaceuticals (Daiichi Sankyo) Cobalamin API Product Portfolio
- 4.9.5 Luitpold Pharmaceuticals (Daiichi Sankyo) Recent Developments
- 4.10 Jamieson
- 4.10.1 Jamieson Company Information
- 4.10.2 Jamieson Business Overview
- 4.10.3 Jamieson Cobalamin API Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Jamieson Cobalamin API Product Portfolio
- 4.10.5 Jamieson Recent Developments
- 4.11 Endo International
- 4.11.1 Endo International Company Information
- 4.11.2 Endo International Business Overview
- 4.11.3 Endo International Cobalamin API Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Endo International Cobalamin API Product Portfolio
- 4.11.5 Endo International Recent Developments
- 4.12 CCEPCD
- 4.12.1 CCEPCD Company Information
- 4.12.2 CCEPCD Business Overview
- 4.12.3 CCEPCD Cobalamin API Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 CCEPCD Cobalamin API Product Portfolio
- 4.12.5 CCEPCD Recent Developments
- 4.13 Bayer HealthCare
- 4.13.1 Bayer HealthCare Company Information
- 4.13.2 Bayer HealthCare Business Overview
- 4.13.3 Bayer HealthCare Cobalamin API Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Bayer HealthCare Cobalamin API Product Portfolio
- 4.13.5 Bayer HealthCare Recent Developments
- 4.14 ANGELINI
- 4.14.1 ANGELINI Company Information
- 4.14.2 ANGELINI Business Overview
- 4.14.3 ANGELINI Cobalamin API Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 ANGELINI Cobalamin API Product Portfolio
- 4.14.5 ANGELINI Recent Developments
5 Global Cobalamin API Market Scenario by Region
- 5.1 Global Cobalamin API Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Cobalamin API Sales by Region: 2021-2032
- 5.2.1 Global Cobalamin API Sales by Region: 2021-2026
- 5.2.2 Global Cobalamin API Sales by Region: 2027-2032
- 5.3 Global Cobalamin API Revenue by Region: 2021-2032
- 5.3.1 Global Cobalamin API Revenue by Region: 2021-2026
- 5.3.2 Global Cobalamin API Revenue by Region: 2027-2032
- 5.4 North America Cobalamin API Market Facts & Figures by Country
- 5.4.1 North America Cobalamin API Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Cobalamin API Sales by Country (2021-2032)
- 5.4.3 North America Cobalamin API Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Cobalamin API Market Facts & Figures by Country
- 5.5.1 Europe Cobalamin API Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Cobalamin API Sales by Country (2021-2032)
- 5.5.3 Europe Cobalamin API Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Cobalamin API Market Facts & Figures by Country
- 5.6.1 Asia Pacific Cobalamin API Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Cobalamin API Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Cobalamin API Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Cobalamin API Market Facts & Figures by Country
- 5.7.1 South America Cobalamin API Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Cobalamin API Sales by Country (2021-2032)
- 5.7.3 South America Cobalamin API Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Cobalamin API Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Cobalamin API Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Cobalamin API Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Cobalamin API Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Cobalamin API Sales by Type (2021-2032)
- 6.1.1 Global Cobalamin API Sales by Type (2021-2032) & (t)
- 6.1.2 Global Cobalamin API Sales Market Share by Type (2021-2032)
- 6.2 Global Cobalamin API Revenue by Type (2021-2032)
- 6.2.1 Global Cobalamin API Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Cobalamin API Revenue Market Share by Type (2021-2032)
- 6.3 Global Cobalamin API Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Cobalamin API Sales by Application (2021-2032)
- 7.1.1 Global Cobalamin API Sales by Application (2021-2032) & (t)
- 7.1.2 Global Cobalamin API Sales Market Share by Application (2021-2032)
- 7.2 Global Cobalamin API Revenue by Application (2021-2032)
- 7.2.1 Global Cobalamin API Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Cobalamin API Revenue Market Share by Application (2021-2032)
- 7.3 Global Cobalamin API Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Cobalamin API Value Chain Analysis
- 8.1.1 Cobalamin API Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Cobalamin API Production Mode & Process
- 8.2 Cobalamin API Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Cobalamin API Distributors
- 8.2.3 Cobalamin API Customers
9 Global Cobalamin API Analyzing Market Dynamics
- 9.1 Cobalamin API Industry Trends
- 9.2 Cobalamin API Industry Drivers
- 9.3 Cobalamin API Industry Opportunities and Challenges
- 9.4 Cobalamin API Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst